Anavex 2-73 Shows Promise in Long-Term Parkinson’s Disease Treatment
Anavex Life Sciences has announced encouraging results from an extension study of their
investigational treatment, Anavex 2-73, in patients with Parkinson’s disease
dementia. Over the course of one year, Anavex 2-73 demonstrated a significant
reduction in symptom severity for 20 participants.
The extension study followed a Phase 2 trial, labeled ANAVEX 2-73-PDD-001, which initially tested
the drug against a placebo in 132 adults. During the gap between the Phase 2
trial and the extension study, participants experienced a notable worsening of symptoms,
underscoring the potential efficacy of Anavex 2-73. The improvement in symptoms
during the extension study suggests that continuous treatment with Anavex 2-73 could play a crucial role in managing Parkinson’s disease dementia.
Christopher Missling, PhD, the president and CEO of Anavex Life Sciences, stated,
“This data suggests Anavex 2-73’s potential capability to slow and
potentially reverse the life-altering symptoms of Parkinson’s disease, an
urgent unmet global need.” This statement highlights the importance of
ongoing research in this area.
Anavex 2-73 works by activating the SIGMAR1 receptor protein, which is pivotal in maintaining
healthy brain cells. Given that lower levels of SIGMAR1 are found in
individuals with Parkinson’s, Alzheimer’s, and Rett syndrome, Anavex Life Sciences is developing Anavex 2-73 as a potential treatment for
these conditions.
The upcoming Phase 3 trial aims to further validate these findings by focusing on whether six
months of treatment with Anavex 2-73 can significantly improve motor and
non-motor symptoms. If successful, Anavex Life Sciences plans to use these
results to support regulatory applications for the therapy’s approval.
Anavex Life Sciences is also providing ongoing access to Anavex 2-73 through a
compassionate use scheme for participants who completed the extension trial,
some of whom have now been on the treatment for over two years. This continued
access underscores the potential long-term benefits and safety of Anavex 2-73.
Refer to this article to learn more.
More about Anavex Life Sciences on https://www.biospace.com/article/releases/anavex-life-sciences-reports-fiscal-2024-first-quarter-financial-results-and-provides-business-update/